Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,372 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Risk factors for thromboembolic events in patients with paroxysmal nocturnal hemoglobinuria (PNH): a nested case-control study in the International PNH Registry.
Höchsmann B, Peffault de Latour R, Hill A, Röth A, Devos T, Patriquin CJ, Chou WC, Jain D, Zu K, Wu C, Lee JW. Höchsmann B, et al. Among authors: jain d. Ann Hematol. 2023 Nov;102(11):2979-2988. doi: 10.1007/s00277-023-05402-3. Epub 2023 Sep 5. Ann Hematol. 2023. PMID: 37668788 Free PMC article.
Addition of danicopan to ravulizumab or eculizumab in patients with paroxysmal nocturnal haemoglobinuria and clinically significant extravascular haemolysis (ALPHA): a double-blind, randomised, phase 3 trial.
Lee JW, Griffin M, Kim JS, Lee Lee LW, Piatek C, Nishimura JI, Carrillo Infante C, Jain D, Liu P, Filippov G, Sicre de Fontbrune F, Risitano A, Kulasekararaj AG; ALXN2040-PNH-301 Investigators. Lee JW, et al. Among authors: jain d. Lancet Haematol. 2023 Dec;10(12):e955-e965. doi: 10.1016/S2352-3026(23)00315-0. Lancet Haematol. 2023. PMID: 38030318 Clinical Trial.
Terminal complement inhibition and control of hemolysis in patients with paroxysmal nocturnal hemoglobinuria who switched from high-dose eculizumab to ravulizumab: a phase IV, single-arm clinical trial.
Griffin M, Gandhi S, Kelly RJ, Munir T, Trikha R, Hicks E, Jain D, Ogawa M, Yu J, Muus P, Kulasekararaj AG. Griffin M, et al. Among authors: jain d. Haematologica. 2024 Nov 28. doi: 10.3324/haematol.2024.285553. Online ahead of print. Haematologica. 2024. PMID: 39605209 Free article.
Inhibiting de novo lipogenesis identifies a therapeutic vulnerability in therapy-resistant colorectal cancer.
Jog E, Jainarayanan AK, La Ferlita A, Chakraborty A, Dalwai A, Yahya S, Shivashankar A, Choudhary BS, Chandramouli A, Kazi M, Jain D, Khapare N, B A, Khan BK, Gera P, Patil P, Thorat R, Verma N, Sehgal L, Saklani A, Kamat SS, Dalal SN, Chaudhary N. Jog E, et al. Among authors: jain d. Redox Biol. 2024 Dec 11;79:103458. doi: 10.1016/j.redox.2024.103458. Online ahead of print. Redox Biol. 2024. PMID: 39705849 Free article.
2,372 results